mathom/ct_dataset huggingface dataset:
Trial Id: Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging Recruitment Status: Withdrawn Trail description: The investigators have developed imaging protocols to monitor and predict breast cancer response to neoadjuvant chemotherapy, both prior to and as early as possible during the course of treatment.

The efficacy and practicality of conventional imaging approaches in the neoadjuvant chemotherapy setting varies and identifies the need for alternate functional imaging strategies. Diffuse optical spectroscopic imaging is an experimental imaging method that allows patients to be followed from baseline through treatment and surgery with a cost-effective, bedside, handheld scanning probe. The researcher evaluates a harmonized diffuse optical spectroscopic imaging technology platform that has been standardized for neoadjuvant chemotherapy monitoring. Diffuse optical spectroscopic imaging is an academic research platform that is non-invasive. Studies will be performed in five clinical sites on approximately 60 neoadjuvant chemotherapy patients. Inclusion Criteria: Female, 18 years of age or older, non pregnant or nursing.
Diagnosis of breast cancer and will be receiving chemo therapy treatments Exclusion Criteria: 18 years of age or younger, pregnant or nursing.
Previous treatment including chemo therapy, radiation, surgery, and hormone therapy.
Previous diagnosis with other form of cancer.
Provide description for trial id: NCT01257932  
 The investigators have developed imaging protocols to monitor and predict breast cancer response to neoadjuvant chemotherapy, both prior to and as early as possible during the course of treatment.

The efficacy and practicality of conventional imaging approaches in the neoadjuvant chemotherapy setting varies and identifies the need for alternate functional imaging strategies. Diffuse optical spectroscopic imaging is an experimental imaging method that allows patients to be followed from baseline through treatment and surgery with a cost-effective, bedside, handheld scanning probe. The researcher evaluates a harmonized diffuse optical spectroscopic imaging technology platform that has been standardized for neoadjuvant chemotherapy monitoring. Diffuse optical spectroscopic imaging is an academic research platform that is non-invasive. Studies will be performed in five clinical sites on approximately 60 neoadjuvant chemotherapy patients.
Trial Id: Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer Recruitment Status: Not yet recruiting Trail description: To analyze the metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer. Inclusion Criteria: Have hormone receptor (HR) positive [estrogen receptor( ER)+/progesterone receptor (PR)+, ER+/PR- or ER-/PR+)/Her2 negative breast cancer previously diagnosed by biopsy.
Have early stage, clinical or anatomic stage I, II or III breast cancer (cT1cN0, cT1cN1, cT2N0, cT2N1, cT3N0)
Candidates for intended curative primary resection who have not had neoadjuvant therapy (endocrine/hormonal therapy, chemotherapy with or without immunotherapy).
Willing to undergo mandatory intraoperative small excisional and core biopsies (4-6 passes) of tumor and normal tissue for research purposes at the time of proposed surgical resection. Exclusion Criteria: Is currently enrolled, or will enroll in, a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study.
Has triple negative (ER-/PR-/Her2-) or HER2+ breast cancer.
Concomitant active malignancy
Is of child-bearing potential who has not had a recent negative pregnancy test done outside of this clinical trial (i.e., as part of standard preparation for diagnosis and treatment for her cancer)
Provide inclusion criteria for trial id: NCT05736367  
 Have hormone receptor (HR) positive [estrogen receptor( ER)+/progesterone receptor (PR)+, ER+/PR- or ER-/PR+)/Her2 negative breast cancer previously diagnosed by biopsy.
Have early stage, clinical or anatomic stage I, II or III breast cancer (cT1cN0, cT1cN1, cT2N0, cT2N1, cT3N0)
Candidates for intended curative primary resection who have not had neoadjuvant therapy (endocrine/hormonal therapy, chemotherapy with or without immunotherapy).
Willing to undergo mandatory intraoperative small excisional and core biopsies (4-6 passes) of tumor and normal tissue for research purposes at the time of proposed surgical resection.
Provide exclusion criteria for trial id: NCT05736367  
 Is currently enrolled, or will enroll in, a different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study.
Has triple negative (ER-/PR-/Her2-) or HER2+ breast cancer.
Concomitant active malignancy
Is of child-bearing potential who has not had a recent negative pregnancy test done outside of this clinical trial (i.e., as part of standard preparation for diagnosis and treatment for her cancer)
Trial Id: Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis Recruitment Status: Completed Trail description: This is a Prospective Clinical Trial without drugs, to determine the HER2 status in the metastasis of patients with primary breast cancer HER2. 32 Sites have been taking part in this Clinical Trial. Inclusion Criteria: Patients who have given their written informed consent to participate in the study.
Women over 18 years.
Breast cancer locally recurrent or metastatic at first relapse or after successive progressions.
Patient has to have available a sample of the primary tumor in paraffin.
Patients who are planning for the next 6 weeks, the biopsy (fine needle aspiration / drainage of fluid cavities, open biopsy, core biopsy) of locally recurrent or metastatic lesion [local relapse in the chest wall, nodal , cutaneous or subcutaneous metastases, peripheral lymph nodes and other soft tissues accessible, bone metastases, visceral metastases (lung, liver, brain, etc..) or pleural effusion / ascites / pericardial / cerebrospinal] according to clinical practice center. Exclusion Criteria: Patients with cognitive impairment that might impede a proper understanding of the written informed consent, according to medical criteria.
Ipsilateral breast local relapses or contralateral breast away.
Patients diagnosed with a second neoplasm, with the exception of cervical carcinoma in situ and non-melanoma skin carcinoma treated properly.
Provide inclusion criteria for trial id: NCT01377363  
 Patients who have given their written informed consent to participate in the study.
Women over 18 years.
Breast cancer locally recurrent or metastatic at first relapse or after successive progressions.
Patient has to have available a sample of the primary tumor in paraffin.
Patients who are planning for the next 6 weeks, the biopsy (fine needle aspiration / drainage of fluid cavities, open biopsy, core biopsy) of locally recurrent or metastatic lesion [local relapse in the chest wall, nodal , cutaneous or subcutaneous metastases, peripheral lymph nodes and other soft tissues accessible, bone metastases, visceral metastases (lung, liver, brain, etc..) or pleural effusion / ascites / pericardial / cerebrospinal] according to clinical practice center.
Trial Id: PROSPR/PCIPS Project 3: Communication of Personalized Breast Cancer Risk Recruitment Status: Completed Trail description: In order to better communicate personal risk of breast cancer to women who have not yet initiated breast cancer screening (mammography), The Annenberg School of Communication at the University of Pennsylvania has created a personal breast cancer screening decision aid tool. This tool will be pilot tested, and then implemented and tested in nine primary care and OB/GYN practices within the University of Pennsylvania Health System. Inclusion Criteria: Women ages 39-48
Patient of one of the nine primary care or OB/GYN practices that are participating in the study
Must have had an appointment at one of these locations in the past 24 months
Must have an appointment during the study period
Woman has not yet initiated breast cancer screening (no prior mammogram)
No history of breast cancer Exclusion Criteria: Prior diagnosis of breast cancer
Major comorbidity that substantially affects their 10 year mortality
Non-English speaker
Trial Id: Detection of Circulating Tumor Cells in Breast Cancer Patients Using a Novel Microfluidic and Raman Spectrum Device Recruitment Status: Unknown status Trail description: Circulating tumor cells (CTCs) in peripheral blood originate from breast cancer (primary and metastatic lesions) shedding. Utilization of CTCs as novel and noninvasive tests for diagnosis confirmation, therapy selection, and cancer surveillance is a rapidly growing area of interest. In this project, the investigators will explore a novel detection technology of circulating tumor cells in breast cancer using novel Microfluidic and Raman Spectrum Device. The primary objective is to demonstrate that the CTC assay counts technology can distinguish between healthy subjects and malignant breast cancer subjects. The secondary objective is to demonstrate that the CTCs detection technology can evaluate the efficacy of chemotherapy and neoadjuvant chemotherapy, as well as dynamic treatment monitoring and prognosis evaluation. Inclusion Criteria: All subjects need to sign the informed consent form.
Age of at least 20 and at most 70 years.
Cancer group subjects with pathology report confirmed to be malignant.
Chemotherapy is necessary before or after surgery.
Control group need to have mammogram /ultrasound results category1-3.
Patients must be available for and compliant to treatment and follow-up. Exclusion Criteria: Not willing to sign the informed consent form.
Pregnant or lactating patients.
Prior or concomitant secondary malignancy.
Any other serious medical pathology, such as congestive heart failure.
Other condition which may affect the CTC results.
Males.
Provide inclusion criteria for trial id: NCT04239105  
 All subjects need to sign the informed consent form.
Age of at least 20 and at most 70 years.
Cancer group subjects with pathology report confirmed to be malignant.
Chemotherapy is necessary before or after surgery.
Control group need to have mammogram /ultrasound results category1-3.
Patients must be available for and compliant to treatment and follow-up.
Provide description for trial id: NCT04239105  
 Circulating tumor cells (CTCs) in peripheral blood originate from breast cancer (primary and metastatic lesions) shedding. Utilization of CTCs as novel and noninvasive tests for diagnosis confirmation, therapy selection, and cancer surveillance is a rapidly growing area of interest. In this project, the investigators will explore a novel detection technology of circulating tumor cells in breast cancer using novel Microfluidic and Raman Spectrum Device. The primary objective is to demonstrate that the CTC assay counts technology can distinguish between healthy subjects and malignant breast cancer subjects. The secondary objective is to demonstrate that the CTCs detection technology can evaluate the efficacy of chemotherapy and neoadjuvant chemotherapy, as well as dynamic treatment monitoring and prognosis evaluation.
Trial Id: Mobile Application Support for Women With Breast Cancer Undergoing Chemotherapy Recruitment Status: Recruiting Trail description: Mobile phones have become an essential tool for everyday life. The convenience and easy accessibility of the data and information received through mobile phones have made mobile applications as the latest trend to provide education for patients in medical centers. In Taiwan, breast cancer incidence has been the highest among all cancers and the fourth leading cause of cancer deaths in women. Women with breast cancer who are undergoing chemotherapy suffer from a number of symptoms throughout the chemotherapy treatment that detrimentally affects their quality of life. Thus, providing social support and nursing care aids for these vulnerable women is imperative to help them face their breast cancer challenges. This study will develop a Mobile device application providing medical care information and social support for breast cancer women during their chemotherapy treatment to help them receive individually tailored information related to chemotherapy and support from healthcare professionals and peers. This study will use a mixed-methods design to develop a Mobile device application based on breast cancer literature and the clinical experiences of breast cancer patients to fulfill the needs women may experience during the chemotherapy treatment. Women with breast cancer will be invited to help refine the Mobile device application's content based on their experiences and feedback about the mobile application. Upon completing the mobile application development, women with breast cancer patients will be recruited to participate in a randomized controlled trial to examine the effectiveness of the mobile application. The results of this study will provide a foundation to deliver a remote, personalized, and continuous health care model to improve the self-efficacy, social support, and quality of life of women with breast cancer, and ultimately enhancing the overall quality of care and patient satisfaction with the medical care participants receive. Inclusion Criteria: at least 20 years of age.
diagnosed with breast cancer for the first time.
treated with chemotherapy at the study sites.
able to access the internet with a mobile phone.
Fluent in spoken and written Chinese . Exclusion Criteria: patients with cognitive dysfunction.
diagnosed mental health problems.
having with other cancers.
Provide description for trial id: NCT05072197  
 Mobile phones have become an essential tool for everyday life. The convenience and easy accessibility of the data and information received through mobile phones have made mobile applications as the latest trend to provide education for patients in medical centers. In Taiwan, breast cancer incidence has been the highest among all cancers and the fourth leading cause of cancer deaths in women. Women with breast cancer who are undergoing chemotherapy suffer from a number of symptoms throughout the chemotherapy treatment that detrimentally affects their quality of life. Thus, providing social support and nursing care aids for these vulnerable women is imperative to help them face their breast cancer challenges. This study will develop a Mobile device application providing medical care information and social support for breast cancer women during their chemotherapy treatment to help them receive individually tailored information related to chemotherapy and support from healthcare professionals and peers. This study will use a mixed-methods design to develop a Mobile device application based on breast cancer literature and the clinical experiences of breast cancer patients to fulfill the needs women may experience during the chemotherapy treatment. Women with breast cancer will be invited to help refine the Mobile device application's content based on their experiences and feedback about the mobile application. Upon completing the mobile application development, women with breast cancer patients will be recruited to participate in a randomized controlled trial to examine the effectiveness of the mobile application. The results of this study will provide a foundation to deliver a remote, personalized, and continuous health care model to improve the self-efficacy, social support, and quality of life of women with breast cancer, and ultimately enhancing the overall quality of care and patient satisfaction with the medical care participants receive.
Trial Id: Breast Cancer Proteomics and Molecular Heterogeneity Recruitment Status: Recruiting Trail description: Primary objective:

The primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes

Secondary objective:

To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes.
To relate proteomic findings to survival data
To identify potential serum markers of breast cancer progression Inclusion Criteria: None Exclusion Criteria: None
Provide description for trial id: NCT01840293  
 Primary objective:

The primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes

Secondary objective:

To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes.
To relate proteomic findings to survival data
To identify potential serum markers of breast cancer progression
Trial Id: Circulating Cancer Cells/Macrophage HYbrid Cells in Patients With Breast Cancer. Recruitment Status: Completed Trail description: Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating cancer cell/macrophage hybrid cells in the peripheral blood.

The study will be conducted on a population of patients with breast cancer (regardless of stage of the disease and the immunohistochemical subtype).

For each included patient, blood samples will be taken and tumor specimens will be collected for the study.

At the end of the blood collection, the patient will have completed his participation in the study. Inclusion Criteria: Patient with breast cancer of any stage (stage I, II, III or IV) and any immunohistochemical subtype (triple-negative, HR+/HER2-negative or HER2-positive).
Patient not yet initiated on specific treatment for the stage of breast cancer at inclusion.
Available tumor sample (archived tumor block) : initial tumor or metastasis depending on the stage of the disease and availability.
Age ≥ 18 years old.
Patient affiliated to a Social Health Insurance in France.
Patient having signed informed consent prior to inclusion in the study and prior to any specific study procedure. Exclusion Criteria: Associated pathology(ies) that may prevent the proper conduct of the procedure under consideration.
Pregnant or breastfeeding woman.
Any psychological, family, geographical or sociological condition that prevents compliance with the medical follow-up and/or procedures of the study protocol.
Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship protection of justice).
Patient who has presented another solid tumor (except breast or cervix carcinoma in situ) within 5 years.
Provide inclusion criteria for trial id: NCT04818125  
 Patient with breast cancer of any stage (stage I, II, III or IV) and any immunohistochemical subtype (triple-negative, HR+/HER2-negative or HER2-positive).
Patient not yet initiated on specific treatment for the stage of breast cancer at inclusion.
Available tumor sample (archived tumor block) : initial tumor or metastasis depending on the stage of the disease and availability.
Age ≥ 18 years old.
Patient affiliated to a Social Health Insurance in France.
Patient having signed informed consent prior to inclusion in the study and prior to any specific study procedure.
Provide exclusion criteria for trial id: NCT04818125  
 Associated pathology(ies) that may prevent the proper conduct of the procedure under consideration.
Pregnant or breastfeeding woman.
Any psychological, family, geographical or sociological condition that prevents compliance with the medical follow-up and/or procedures of the study protocol.
Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship protection of justice).
Patient who has presented another solid tumor (except breast or cervix carcinoma in situ) within 5 years.
Provide description for trial id: NCT04818125  
 Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating cancer cell/macrophage hybrid cells in the peripheral blood.

The study will be conducted on a population of patients with breast cancer (regardless of stage of the disease and the immunohistochemical subtype).

For each included patient, blood samples will be taken and tumor specimens will be collected for the study.

At the end of the blood collection, the patient will have completed his participation in the study.
Trial Id: Evaluation of Patients With Breast Cancer Using DCE-MRI, MRS, and Proteomics Recruitment Status: Completed Trail description: RATIONALE: Diagnostic procedures, such as dynamic contrast-enhanced magnetic resonance imaging(DCE-MRI), magnetic resonance spectroscopy (MRS), and tissue proteomics, may help doctors find and diagnose breast cancer and plan the best treatment.

PURPOSE: This clinical trial is studying MRI and MRS with or without tissue proteomics analysis to see how well they work in evaluating healthy women and women who are undergoing surgery for breast cancer. Inclusion Criteria: None Exclusion Criteria: None
Provide description for trial id: NCT00656604  
 RATIONALE: Diagnostic procedures, such as dynamic contrast-enhanced magnetic resonance imaging(DCE-MRI), magnetic resonance spectroscopy (MRS), and tissue proteomics, may help doctors find and diagnose breast cancer and plan the best treatment.

PURPOSE: This clinical trial is studying MRI and MRS with or without tissue proteomics analysis to see how well they work in evaluating healthy women and women who are undergoing surgery for breast cancer.
Trial Id: Awareness Scale Related To Physiotherapy After Breast Cancer: A Scale Development Study Recruitment Status: Recruiting Trail description: In this study, the aim is to develop a scale that assesses the awareness levels of particularly short and/or long-term effects, especially related to physiotherapy, in individuals diagnosed with high incidence and survival rates of breast cancer. Inclusion Criteria: Be over 18 years old
Be woman
Being diagnosed with breast cancer (individuals diagnosed with breast cancer who will start, start or have completed breast cancer treatment)
Being able to read and understand the Turkish language Exclusion Criteria: Having a cognitive impairment that interferes with answering questions
Be man
Trial Id: Big Data and Text-mining Technologies Applied for Breast Cancer Medical Data Analysis Recruitment Status: Unknown status Trail description: Primary purpose :

To develop a method to automatically extract and structure the information included in numerous medical records from breast cancer patients.

Secondary purpose :

With this procedure we can analyze the content of ten thousand anonymized textual medical records.

This information should enable us to explore many subjects, such as:

The impact of certain therapeutic procedures
The characteristics of sub-groups of patients
Pregnancy associated breast cancers
Risk factors Inclusion Criteria: Majority (age > 18)
Malignant breast tumors
signed informed consent Exclusion Criteria: Benign breast pathology
Patients not initially treated at the Hôpitaux Universitaires de Strasbourg
Provide description for trial id: NCT02810093  
 Primary purpose :

To develop a method to automatically extract and structure the information included in numerous medical records from breast cancer patients.

Secondary purpose :

With this procedure we can analyze the content of ten thousand anonymized textual medical records.

This information should enable us to explore many subjects, such as:

The impact of certain therapeutic procedures
The characteristics of sub-groups of patients
Pregnancy associated breast cancers
Risk factors